Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies Inks Partnership to Integrate MRD Assay With Epic's EMR System

NEW YORK – Adaptive Biotechnologies said on Tuesday that it has foraged a partnership with Epic Systems to integrate the ClonoSeq assay into Epic's electronic medical record (EMR) system.

The integration will allow providers using the Epic system to order ClonoSeq, an in vitro diagnostic (IVD) test for monitoring minimal residual disease (MRD), from Adaptive and review results in the same way as they would with tests directly carried out at the site of care. The collaboration with Epic will commence immediately, with ClonoSeq integration expected to go live in 2023, the company said.

Building on this partnership, Seattle-based Adaptive said it will continue to pursue integration opportunities with other EMR vendors, particularly those with leading positions in community oncology. Meanwhile, the company will continue to enable ClonoSeq ordering and reporting through its secure online portal and via its partnership with Labcorp.

"EMR integration is clearly the path forward to expanding access and increasing ease of use for advanced oncology tests like ClonoSeq," said Nitin Sood, Adaptive’s chief commercial officer for MRD business. "MRD is most powerful when monitored serially over time, and Epic integration will enable providers to efficiently leverage ClonoSeq MRD results at multiple points in the patient care continuum." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.